Open Access<p>GRHL2 Upregulation Predicts a Poor Prognosis and Promotes the Resistance of Serous Ovarian Cancer to Cisplatin</p>
Author(s) -
Yanting Nie,
Yiling Ding,
Mengyuan Yang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s250412
Subject(s) - gene knockdown , small hairpin rna , cisplatin , cancer research , ovarian cancer , apoptosis , mapk/erk pathway , downregulation and upregulation , carcinogenesis , cell growth , chemistry , biology , microbiology and biotechnology , signal transduction , cancer , medicine , chemotherapy , gene , biochemistry
GRHL2 has been shown to function in ovarian carcinogenesis. However, the relationship between GRHL2 and cisplatin (DDP) resistance in serous ovarian cancer (SOC) is not clear. The purpose of this study was to elucidate the function and mechanism of GRHL2 in DDP resistance of SOC.